OMER Omeros Corporation

18.49
-0.03  -0%
Previous Close 18.52
Open 18.52
Price To Book -9.06
Market Cap 906226980
Shares 49,011,735
Volume 107,004
Short Ratio
Av. Daily Volume 649,196

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced January 2, 2018.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Phase 2 data released October 1, 2018 showed only marginal improvement compared with placebo.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 trial initiation announced July 17, 2018.
OMS527
Nicotine Addiction

Latest News

  1. Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
  2. Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
  3. What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
  4. Edited Transcript of OMER earnings conference call or presentation 1-Mar-19 1:30pm GMT
  5. Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
  6. Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
  7. Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
  8. Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
  9. Why Omeros Stock Jumped Today
  10. Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
  11. Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
  12. Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register?
  13. Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data
  14. Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
  15. Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
  16. Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
  17. Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
  18. Omeros Announces Research Collaboration with University of Cambridge
  19. Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
  20. Omeros Announces Additions to Senior Management Team